Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer

Abstract

This analysis adds to the clinical evidence base that use of ICIs before SARS-CoV-2 infection does not affect COVID-19 severity or survival outcomes, supporting the continued use of ICIs in cancer patients during the pandemic.